Looks like nobody home today Greg :)Greg what are your thoughts...

Looks like nobody home today Greg :)

Greg what are your thoughts with regards to Abagovomab hitting the market prior to Cvac.

Sounds promising and most likely will be the first ovarian cancer vaccine to hit the market if it clears the final hurdle.

Began it's Phase2/3 FDA trial back in 2006,currently has over 800 patients enrolled.

Phase 2 results were excellant enabling Menarini to continue the trial into Phase 3....

""In a Phase II study on 119 patients with advanced ovarian cancer in which the standard therapies had already been ineffective, treatment with abagovomab led to a prolongation of survival time (23.4 months compared to 4.9 months) in those patients who responded to the vaccination, i.e. those in whom the formation of antibodies against the tumour was proven (almost 70 % of patients). The vaccine showed hardly any side effects in preliminary studies.""

Phase 3 results expected in the first half of this year.


Menarini had a turnover of over $3 billion Euro in 2010 so they shouldn't have a problem funding the commersilation.

http://www.clinicaltrials.gov/ct/show/NCT00418574?order=1

http://www.menarini.com/r_d/Mimosa-Project